Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of ACTM-838 as a Single Agent in Patients With Advanced Solid Tumors

NCT06336148 is registered in ClinicalTrials.gov with Actym Therapeutics, Inc. as lead sponsor.

NCT NCT06336148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06336148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of ACTM-838 as a Single Agent in Patients With Advanced Solid Tumors
Lead sponsor
Actym Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
June 5, 2024
Completion date
August 28, 2025
Enrollment
10 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor